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Original Article
Breast cancer in men is a rare disease that accounts for 
around 1% of breast cancer cases in the western world (Ly, 
Forman, Ferlay, Brinton, & Cook, 2013; Miao et al., 2011). 
However, the incidence has risen over the past decades 
(Hodgson, Button, Franceschi, Moffat, & Livingstone, 
2004), and it has been suggested that this rise will continue 
in the future (Contractor, Kaur, Rodrigues, Kulkarni, & 
Singhal, 2008). Risk factors include a family history of 
breast cancer, genetic and hormonal aspects (da Silva, 2016; 
Giordano, 2018). As breast cancer is known as a typical 
woman’s disease, most research to date has focused on 
female breast cancer. Consequently, there is a need for more 
research on male breast cancer (MBC), especially concern-
ing the psychosocial aspects of cancer care. Besides this 
female focus in breast cancer research, there is also a social 
construct that connects breasts in general and breast cancer 
with femaleness (da Silva, 2016). These social constructs 
can have significant implications for men who have breast 
cancer, wherein, besides having to cope with the disease, 
males also have to deal with gender aspects because of suf-
fering from a perceived woman’s illness and feminization in 
therapy (da Silva, 2016). Emasculation is a big issue dis-
cussed in several studies of male breast cancer patients 
(MBCP) (da Silva, 2016; Donovan & Flynn, 2007; France 
et al., 2000; Iredale, Brain, Williams, France, & Gray, 
2006; Smolin & Massie, 2002; Swergold, Murthy, & 
Chamberlain, 2014) and can lead to stigmatization.
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Abstract
Male breast cancer (MBC) is rare and known as a typical woman’s disease. This study is part of the N-MALE project 
(Male breast cancer: patient’s needs in prevention, diagnosis, treatment, rehabilitation and follow-up-care) and aims to 
investigate how MBC patients (MBCP) feel about suffering from a “woman’s disease,” what character the stigmatization 
has, and how it can be prospectively reduced. Therefore, a mixed methods design is applied including data of N = 
27 qualitative interviews with MBCP and quantitative data of N = 100 MBCP. Findings identify a diverse picture, as 
stigmatization varies between contexts and patients: Most stigmatization concentrates on sexual stigmatization and 
ignorance of MBC and mostly occurs in cancer care systems and work-related contexts. The level of stigmatization 
varies with age and amount of treatment methods received, as reported within the created typology of different MBCP 
stigma types. To prospectively reduce stigmatization in MBCP, more publicity of MBC is needed, as well as gender-
neutral communication and information material.
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Stigmatization as a sociological construct was first 
characterized by Goffman (Goffman, 1963). It has been 
variously defined as a process in which specific human 
characteristics, so-called stigmas, are stereotyped and 
negatively labeled (Link & Phelan, 2001; Esser et al., 
2017). Stigmatization can lead to social exclusion, isola-
tion, and changes in the life situation of the affected per-
son such as employment opportunities or housing (Link 
& Phelan, 2006) and has also been reported to influence 
personal identity (Goffman, 1963; Link & Phelan, 2001). 
This labeling process, whether placed by others or one-
self, often includes shame as part of self-stigmatization or 
disapprobation (Goffman, 1963). It is important to distin-
guish between self and external stigmatization, because 
stigmatized people sometimes do not identify themselves 
with the negative labeling of others (Ernst, 2016). 
Stigmatization has an orientation function in social inter-
actions, as it helps to maintain norms and expectable 
behavior. To distance oneself from a stigmatized person 
retains our own identity as it normalizes the own identity 
or depreciates the other (Hohmeier, 1975). Also, as stated 
by Tang, Mayer, Chou, and Hsiao (2016), stigmatization 
is not consistent but depends on personal aspects, social 
relationships, and contexts, as to whether the stigmatized 
person interprets something as stigmatizing or not.
Health-related stigmatization means the labeling of 
people because of certain characteristics of illness (Fife 
& Wright, 2000; Goffman, 1963; Link & Phelan, 2001). 
Illness is a stigmatizing element for the reason that it is 
connected with (physical and/or mental) limitations (Fife 
& Wright, 2000). Stigmatization of individuals, based on 
health in general or illness, typically results in their exclu-
sion from social roles or functions (Link & Phelan, 2001). 
As past studies identify, stigmatization is a very common 
aspect for cancer patients (Ernst, 2016; Fife & Wright, 
2000; Lebel & Devins, 2008), as cancer is a disease that 
confounds the social norms of society and provokes fear 
and insecurity, which is reported and explained in detail 
elsewhere (Ernst, 2016).
Although several studies of stigmatization of (female) 
breast cancer patients (Meacham, Orem, Nakigudde, 
Zujewski, & Rao, 2016; Nyblade, Stockton, Travasso, & 
Krishnan, 2017; Tripathi, Datta, Agrawal, Chatterjee, & 
Ahmed, 2017; Trusson & Pilnick, 2017) exist, no studies, 
to date, have focused solely on stigmatization of MBCP. 
Instead, the issue of MBCP stigmatization is raised 
within the discussion of the patients (Brain, Williams, 
Iredale, France, & Gray, 2006; Donovan & Flynn, 2007; 
Iredale et al., 2006; Kipling, Ralph, & Callanan, 2014). 
Stigmatization plays an important role in MBCP. One 
issue of concern for MBCP surrounds the physical changes 
and changes in body image after treatment (Bunkley, 
Robinson, Bennett, & Gordon, 2000), especially because 
men often associate their body (and their chest) with 
masculinity (Donovan & Flynn, 2007; Pituskin, Williams, 
Au, & Martin-McDonald, 2007; Robinson, Metoyer, & 
Bhayani, 2008). Particularly, the scar on the breast is an 
important contributor to the altered body image, which is 
perceived controversially by the patients (France et al., 
2000; Iredale et al., 2006; Pituskin et al., 2007; Robinson 
et al., 2008; Williams et al., 2003), and younger men 
tend to find it of greater concern than older patients do 
(Iredale et al., 2006). An altered body image is also con-
nected with psychological distress (Brain et al., 2006). 
Additionally, the rareness of the disease, connected with 
a lack of awareness of MBC and the perception of breast 
cancer as a woman’s disease, can lead to isolation 
(Bunkley et al., 2000; Iredale et al., 2006) brought about 
by stigmatization and nondisclosure because of feared 
stigmatization (France et al., 2000; Iredale et al., 2006).
In the context of these aspects raised in the preceding 
text, four major areas were explored to examine how 
MBCP feel about suffering from a “woman’s disease”: 
(a) the contexts in which the stigmatization occurs; (b) 
what kind of stigmatization the patients experience; (c) 
how, from the patients’ perspective, stigmatization can be 
reduced; and (d) if different levels of stigmatization can 
be created and how they differ regarding demographical 
and cancer-related aspects.
Methods
Study Design
This study was approved by the Ethics Committee for 
Bonn (Germany). It was carried out by an interdisciplin-
ary research team (psychology, sociology, and health 
economics) with members representing care providers, 
patient representatives, and a psychotherapist.
The study is part of the N-MALE project (Male breast 
cancer: patient’s needs in prevention, diagnosis, treat-
ment, rehabilitation and follow-up care) conducted in 
Germany. N-MALE, which started in April 2016 and 
ends in March 2018, was undertaken to examine the med-
ical and psychosocial needs of MBCP across the cancer 
care continuum (from prevention to follow-up). It is an 
interdisciplinary study involving the University Hospital 
of Bonn, the University Hospitals of Cologne and Munich 
and the German Cancer Society (DKG). The N-MALE 
study applies a mixed methods design capturing data via 
qualitative interviews with MBCP and a quantitative 
questionnaire. This triangulation of methods intends to 
create more depth and breadth in the analysis of data 
(Carell, 2005; Flick, 1992) and thereby gain more insight 
into the participants’ perspective (Carell, 2005; Denzin & 
Lincoln, 2003). In the following text, qualitative and 
quantitative methods are described successively based on 
the so-called between-method triangulation described by 
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Carell (2005), where both methods—qualitative and 
quantitative—are treated equally. Mixed methods were 
chosen to exploit the strengths of both approaches: the 
exploratory and comprehending character of qualitative 
analysis since little is known about stigmatization of 
MBCP. The qualitative content analysis was performed 
according to Mayring (2016). Data collected from the 
quantitative analysis were used to support the qualitative 
results, as the results of more MBCP can be considered 
within this study because of a bigger number of partici-
pants within the quantitative sample. By using both meth-
ods, the results can validate each other. Furthermore, 
quantitative methods help to describe “facts” as demo-
graphic or disease-related characteristics of the partici-
pants. Results of both analyses are brought together at the 
end of the results section within a mixed methods matrix 
per patient to complement each other to make a typifica-
tion of participants possible.
Data were collected between April 2016 and October 
2017. This process included qualitative and quantitative 
data.
Inclusion Criteria and Participants
Inclusion criteria were the confirmed breast cancer diagno-
sis (C50.x or D05.x) and a written informed consent. 
Exclusion criteria for the interviews were defined as aspects 
that made it difficult to set up an interview and included, for 
example, deafness, speech or comprehension problems, 
psychosis, dementia, advanced cancer, and related issues 
like pain, difficulties in concentrating, or if the written dec-
laration of consent was missing or withdrawn. The exclu-
sion criterion for the quantitative questionnaire was a 
missing or withdrawn declaration of consent.
Access to the field was given through the Men with 
Breast Cancer Network (Netzwerk Männer mit Brustkrebs 
e.V.) and breast cancer centers that were certified in 
accordance with the criteria of North Rhine Westphalia 
State (Äkzert) and the requirements of the German 
Cancer Society (Deutsche Krebsgesellschaft, DKG) and 
the German Society for Breast Diseases (Deutsche 
Gesellschaft für Senologie). Furthermore, MBCP inter-
ested in taking part in the study contacted us via e-mail or 
telephone, as there were some invocations in the form of 
press releases and short articles.
From this number of interested MBCP, participants 
were selected for qualitative interviews. Sampling was 
done according to the precepts of the Glaser and Strauss 
model (2008) for theoretical sampling. This strategy is 
used to find cases as significant and contrasting as possi-
ble until theoretical saturation is reached (Glaser, Strauss, 
& Paul, 2008). For sampling, data of the standardized 
questionnaire was used.1 The interviewed subjects 
included participants varying in sociodemographic factors 
like age, family status (status of relationship, children), 
and education; facts of disease like date of diagnosis 
(recent and less recent), disease status (stage, relapse), and 
treatment (breast cancer center or hospital); and other 
aspects like contact with support group and experiences 
during treatment (positive or negative).
Reasons for nonresponse for the qualitative interviews 
were lack of interest in an interview in general, issues of 
the disease like a progressed stage or cancer-related prob-
lems (exclusion criteria), or death between sending the 
questionnaire and appointment for an interview. For the 
quantitative questionnaire, we have no information of 
reasons for nonresponse.
Data Collection
Qualitative interviews. The recruiting and the participant 
interviews were conducted by two female (and one 
male) research fellows (PhD candidates) of the 
N-MALE project who were trained in interviewing 
skills. One was experienced in interviewing and did an 
advanced intern training of the other interviewers. In 
addition, all interviewers completed an interviewer 
training with a psychotherapist, focusing on how to 
deal with serious situations that could arise within the 
interviews (e.g., strategies for talking about sensitive 
topics, like sexuality of the participants with those who 
have a different gender, how to deal with psychological 
stress that could arise from the interview).
The semistructured face-to-face interviews were done 
according to an interview guideline (Helfferich, 2011), 
which left enough space for open-ended answers and was 
structured along all steps of cancer therapy.2 The guide-
line was developed within the interdisciplinary N-MALE 
team, pilot-tested by three interviews with MBCP, and 
customized as discussed in the results of pretests in the 
project team. Each interview was between 1 and 2 hours 
and was audiotaped, anonymized, and transcribed toward 
specific rules according to Fuß and Karbach (Fuß & 
Karbach, 2014). After each interview, field notes on non-
verbal aspects, abnormalities, first interpretations, and 
other information that could be helpful for the interpreta-
tion were recorded. The participants could choose the 
location of the interview, mostly their place of residence. 
To ensure an undisturbed atmosphere, care was taken to 
exclude others from the interview setting so that only the 
participant and the interviewer were present, except cases 
in which participants requested their partners. Before the 
interview, participants signed an informed consent and 
were advised about the procedure, the study objective, 
and the use of the data.
Quantitative data. The quantitative questionnaire was 
developed within the interdisciplinary N-MALE team 
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and pretested with four MBCP. After the pretests, the 
questionnaire was modified and mailed to all interested 
participants (117 participants).3 Following Dillman’s 
total design survey method (1978), three reminders were 
sent at 1, 3 and 7 weeks, to achieve the highest response 
rate (Dillman, Smyth, & Christian, 2014).
Sociodemographic characteristics. Sociodemographic as- 
pects of the MBCP were measured. They included age, 
marital/relationship status, children, education, occupa-
tion, and residential area (urban, rural).
Disease-related characteristics and breast cancer 
treatment. The participants were asked about aspects 
of their disease, like date of diagnosis, first time breast 
cancer or relapse, and types of cancer treatment (current 
breast cancer treatment, surgery, chemotherapy, adjuvant 
radiation, hormonal therapy, rehabilitation), as well as 
contact with (MBCP) support group, experiences of can-
cer care (positive and negative), and comorbidities.
Measurement of stigmatization. Participants were 
questioned about stigmatization during the course of 
cancer treatment and in private surroundings. The ques-
tionnaire was structured in the different stages of can-
cer care, with filter questions about specific cancer care 
steps, in which the participants were simply required to 
indicate whether they have received in the past or will 
receive it in the future. Concerning stigmatization in the 
process of cancer care, the following five variables were 
used:
(1) Have you felt excluded during hospitalization in 
terms of your breast cancer disease?
(2) Have you felt excluded during chemotherapy in 
terms of your breast cancer disease?
(3) Have you felt excluded during radiation therapy in 
terms of your breast cancer disease?
(4) Have you felt excluded during medical rehabilita-
tion in terms of your breast cancer disease?
(5) Have you felt excluded during aftercare or follow-
up survey in terms of your breast cancer 
disease?
Concerning the private surroundings, the survey asked 
about stigmatization in different circumstances like close 
and wider social relationships, with three variables in 
total:
(1) Have you felt excluded from your family in terms 
of your breast cancer disease?
(2) Have you felt excluded from your friends or 
acquaintances in terms of your breast cancer 
disease?
(3) Have you felt excluded from your colleagues or 
superiors in terms of your breast cancer 
disease?
The answer categories for all questions were never, 
rarely, sometimes, often, and always with single selec-
tion. If men felt any stigmatization, the next question 
asked was in which form they experienced stigmatization 
to explain their experiences. This open-ended answer cat-
egory was also included in the qualitative content 
analysis.
Data Analysis
Analysis of qualitative data. For qualitative analysis, tran-
script data of the interviews, after-interview notes, as 
well as the open-ended answer categories of the quantita-
tive questionnaire (reasons for stigmatization) were ana-
lyzed using qualitative content analysis according to 
Mayring (Mayring, 2016). Coding was deductive and 
inductive4 using MAXQDA version 12.2.1 (VERBI 
GmbH, 2016) software for managing the data. The cod-
ing was described. One scientist who mainly conducted 
the interviews also did the coding process. During this 
process, there were regular consultations within the 
research team for validation. It was an alternating inter-
viewing and analyzing process, where categories were 
developed and tested in the interviews that followed. This 
alternating strategy was also needed for the purposeful 
sampling (Helfferich, 2011). At the end of the coding 
process, the codes were discussed in a research 
workshop.
Statistical analysis. For statistical analysis, SPSS version 
25 (IBM SPSS Statistics, 2017) was used. The sociode-
mographic, disease-related characteristics and breast can-
cer treatment were analyzed using descriptive statistics. 
For analysis of stigmatization, descriptive statistics were 
used as well. Mean values are reported separately for 
each item. Furthermore, t-tests were derived to estimate 
significant differences between items.
Mixed methods analysis. For mixed methods analysis, 
qualitative and quantitative data of 27 MBCP were 
included. Qualitative and quantitative data of those 
participants were merged, including codes of qualita-
tive analysis (dimensions of stigmatization, no subjec-
tive stigma experienced) and data of quantitative 
analysis (context of stigmatization: results per person 
for Measurement of Stigmatization). Sociodemo-
graphic aspects (age, education) and disease-related 
aspects (breast cancer for the first time/ relapse, 
stage(s) in the cancer care system) were collected 
within the interviews.
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Findings
Characteristics of Participants
Concerning quantitative data, the cleared response rate 
was 85,5% (N = 100).
Twenty-seven interviews with MBCP were conducted. 
Table 1 gives an overview of sociodemographic and dis-
ease-related characteristics of the quantitative sample and 
the (qualitative) subsample.
Context of Stigmatization
Findings based on the interviews with MBCP identify 
that most stigmatization occurs in the cancer care system. 
In addition, MBCP feel stigmatized by female breast can-
cer patients, especially if they have the feeling that the 
women are unaware of the disease in men:
“I remember that woman in the breast cancer center. She 
said: ‘What do YOU want here? (Laughing) You don’t 
belong here.’” (ID no. 63)
The statistical analyses (Table 2) indicate that in the 
cancer care system, most stigmatization takes place in 
rehabilitation settings (mean = 1.50), significantly more 
than during chemotherapy (p = .006), radiation (p = .019), 
follow-up survey (p = .031), and within family (p = .004)). 
In the cancer care system, the men experienced signifi-
cantly higher stigmatization during hospitalization 
(mean = 1.20) than during chemotherapy (mean = 1.14; 
p = .049). The experienced stigmatization is higher 
within the cancer care system than within social sur-
roundings. One exception from this finding was the feel-
ing of exclusion in the working environment, which 
showed the highest value (mean = 1.69). The men 
felt significantly more excluded in the working environ-
ment than in hospital (p = .000), during chemotherapy 
(p = .000), radiation (p = .000), follow-up survey (p = .000), 
and within family (p = .000) and friends (p = .000). In 
qualitative data—in contrast—stigmatization is mostly 
being found within the cancer care system. In social sur-
roundings, the closer the relationship, the less the stigma-
tization. That is, there is significantly less stigmatization 
with close family and friends than in broader social set-
tings, for instance, with colleagues.
Categories of Stigmatization
Within the interviews with MBCP, five main categories of 
stigmatization were identified and are shown in Figure 1.
Figure 1. Categories of stigmatization of male breast cancer patients.
The category Experiences of stigmatization is a form 
of direct stigmatization. It describes situations in which 
MBCP were treated differently than other patients. The 
category Bodily dimension includes aspects associated 
with the changes to the body and body image after the 
surgery. In addition, there is a horizontal category of 
indirect stigmatization. Indirect stigmatization comprises 
situations that cause shame and indisposition and can 
lead to self-stigmatization. This category is called Hidden 
and feared stigmatization. Those direct and indirect 
dimensions led to the category Hints for reducing stig-
matization given by the participants.
Experiences of stigmatization. The stigma aspects of most 
of the men are represented within this dimension. Sixteen 
men (59.26%; second highest stigma rate) experienced 
sexual stigmatization in the process of cancer care. This 
dimension of stigmatization occurs the most (Table 3). It 
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includes the aspect that cancer care focuses on female 
breast cancer patients. Also, discrimination in treatment 
was experienced because of being male. For example, 
several men reported that some outpatient gynecologists 
who were specialists for breast cancer rejected them 
because treating a man might cause billing issues. Fur-
thermore, some men were called by a female name in the 
waiting room:
“I think I was called as ‘Mrs. Miller’ once (laughing). 
Something like this is also unpleasant.” (ID no. 95)
The highest stigma rate can be found within the dimen-
sion having the feeling of being the only rooster in the 
yard beside all the women in breast cancer therapy (occurs 
in 18 men; 66.67%). The participants experienced this 
stigma in two different ways. One, from a positive view:
Table 1. Sample Characteristics of the Quantitative and Qualitative Sample of Male Breast Cancer Patients.
N = 100 (N = 27) N (N) % (%) Mean (mean) Min (min) Max (max)
Sociodemographic characteristics
Age  
In years 66.91 (64.8) 39 (42) 89 (89)
Missing 2 (1) 2 (3.7)  
Living with a partner
Yes 82 (19) 87.2 (79.2)  
No 12 (5) 12.8 (20.8)  
Missing 6 (3) 6.0 (11.1)  
Children  
Yes 79 (20) 84.0 (76.9)  
No 15 (6) 16.0 (23.1)  
Missing 6 (1) 6.0 (3.7)  
Education (multiple answers)
No school certificate 2 (0) 2.0 (0.0)  
Lower school certificate 41 (11) 41.8 (42.3)  
Intermediate school certificate 27 (8) 27.6 (30.8)  
Vocational diploma/university 
entrance certificate
35 (11) 35.7 (42.3)  
Missing 2 (1) 2.0 (3.7)  
Occupation
Full-time 26 (7) 26.8 (26.9)  
Part-time 4 (1) 4.1 (3.8)  
Occupational rehabilitation 2 (0) 2.1 (.0)  
Certified sick 12 (6) 12.4 (23.1)  
(Early) retired 54 (12) 55.7 (46.2)  
Unemployed 1 (0) 1.0 (.0)  
Missing 3 (1) 3.0 (3.7)  
Disease-related characteristics
Time since first diagnosis
In years 3.61 (4.1) <1 (<1) 20 (17)
Missing 5 (1) 5 (3.7)  
Types of treatment received  
Surgery 97 (27) 97.0 (100)  
Chemotherapy 56 (16) 56.0 (59.3)  
Radiation therapy 65 (16) 65.0 (59.3)  
Antihormone therapy 75 (22) 75.0 (81.5)  
I don’t know 2 (1) 2.0 (3.7)  
Missing 0 (0) 0 (.0)  
Newly diagnosed
Yes 92 (24) 95.8 (96.0)  
No 4 (1) 4.2 (4)  
Missing 4 (2) 4.0 (7.4)  
Note. Quantitative sample N = 100; qualitative sample (subsample) N = 27. Numbers of qualitative sample are in brackets.
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“You then feel like an exotic. Many women. But me as the 
only man. [. . .] Anyway, you’re the only rooster in the yard.” 
(ID no. 9)
But also from a more negative one:
“I’ve been the only men among women. An exchange of 
experience was not possible at the rehabilitation center.” 
(ID no. 91)
Moreover, 12 men (44.44%; third highest stigma rate) 
experienced ignorance because nearly no one knows about 
breast cancer in men, both in their social and professional 
environments. Also, men experienced changes in social 
relationships, including social isolation, because some peo-
ple do not know how to deal with a man having breast 
cancer.
Although 10 men (37.04%) reported having no experi-
ences of stigmatization, the codes (Table 3) reveal that 
this number is lower (N = 3). Hence, there is a difference 
between the self-reporting of stigmatization (when they 
were asked if they experienced stigmatization) and the 
results of coding concerning stigmatization.5
Bodily dimension. There were four aspects found in which 
the disease influences body issues related to stigmatiza-
tion. Three of them are visible (e.g., the scar on the 
breast). Some men were ashamed to show themselves 
shirtless in public, for example, in a swimming pool. The 
loss of hair is also a problem for some men—on the head 
and especially on the face, that is, loss of the beard:
“This is a time when the disease is also disfiguring. Nobody 
sees the surgery. There is a shirt over it. You have your scars, 
[. . .] but you can hide them. But when the hair is gone, 
mustache away, eyebrows away.” (ID no. 32)
Not visible but also important for the men is the 
change in body image after the disease. Some men felt 
emaciated and less strong:
“This was a big problem for me at the beginning. Because 
I said, I’m distorted. The nipple is gone. [.] It was a 
learning process. [. . .] I have a certain body image of 
mine. I’m tall, I’m strong, I’m intact, I’m in working 
order. I’m reasonably good looking. And at that time, this 
body image got a first crack. [. . .] Some years ago, I had 
a hip replacement surgery. There is also a scar. That 
didn’t matter to me. Only here I had doubts.” (ID no. 77)
Hidden and feared stigmatization. Within this indirect 
dimension of stigmatization, some men mentioned 
receiving questioning glances while sitting in the waiting 
room of a gynecologist:
“[While sitting in the waiting room] the women are thinking: 
‘He accompanies his wife. She’s in treatment.’ And when 
you’re being called: ‘Mr. Miller please.’ All heads are 
turning, and you feel kind of observed.” (ID no. 55)
Besides, participants had the feeling of being an odd-
ity or outsider because of being the only male and not 
being integrated into the circle of female breast cancer 
patients:
“Well, in those occupational therapies there are 
predominantly women. [. . .] My impression was that they 
did not want to have men with them. [. . .] That’s why I kept 
out of it.” (ID no. 16)
Table 2. Stigmatization of Male Breast Cancer Patients (N = 100).
N Range Minimum Maximum
Mean 
value
Standard 
deviation Significance in reference to (p)a
Excluded during 
hospitalization
97 1–5 1 4 1.20 .606 Chemo (.049), radiation (.017), family 
(.016), colleagues (–) (.000)
Excluded during 
chemotherapy
57 1–5 1 3 1.14 .398 Rehab (–) (.006), colleagues (–) (.000)
Excluded during radiation 
therapy
62 1–5 1 3 1.10 .349 Rehab (–) (.019), colleagues (–) (.000)
Excluded during medical 
rehabilitation
48 1–5 1 5 1.50 .968 Follow-up (.031),
family (.004)
Excluded during aftercare 
or follow-up survey
80 1–5 1 4 1.14 .497 Colleagues (–) (.000)
Excluded from family 100 1–5 1 3 1.05 .297 Friends (–) (.011), colleagues (–) (.000)
Excluded from friends or 
acquaintances
100 1–5 1 3 1.16 .487 Colleagues (–) (.000)
Excluded from colleagues 
or superiors
94 1–5 1 5 1.69 .776  
Valid terms (list wise) 28  
Note. aFor interpreting the terms: Positive values indicate higher feelings of exclusion within the term than within the comparative value.
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In treatment, some men also had the sense of being 
treated differently from the women with breast cancer. 
Moreover, men reported fear of other people’s reactions 
that made them ashamed of their disease:
“I was ashamed at first [. . .]. Because men and breast 
cancer? [. . .] It’s the basis of several thoughts as: That 
could provoke mockery or strange questions. How can a 
man get breast cancer. [. . .] And I thought didn’t tell anyone 
at first.” (ID no. 99)
Hints for reducing stigmatization. From the men’s perspec-
tive, stigmatization can be reduced in two different ways. 
One is by increasing the awareness of MBC in the cancer 
care system and in public:
“Thus, enlightenment is the most important. In therapy, it 
should be taken for granted that also men can get breast 
cancer and that it isn’t extraordinary.” (ID no. 16)
“If the people were more enlightened, there would be less 
insecurity in social environment, I guess.” (ID no. 32)
Second, the men wish for equality of men and women 
in cancer care. Notably, the documents and information 
materials should be gender-neutral or contain aspects for 
both genders:
“As I said those forms. . . . It always annoys me. [. . .] Why 
it isn’t possible to create a form which says dear patient 
[female AND male salutation].” (ID no. 32)
Stigma Types
As the mixed methods matrix (Table 3) indicates, most 
of the 27 participants experienced stigmatization during 
their course of the disease. However, the level of stig-
matization varies between the participants. The partici-
pants were divided into three different groups according 
to their experiences of stigmatization (how many expe-
riences of stigmatization and number of areas the stig-
matization was experienced).6 To allocate the MBCP 
into those three stigma groups, their answers within the 
questionnaire and the interview were added, concerning 
stigmatization.
The first group “not stigmatized” experienced no or 
minimum stigmatization. It includes participants who in 
the interview said they experienced no stigmatization and 
who had no hint of any stigma dimension within the cod-
ing of the interviews (or just one) and stated in the ques-
tionnaire that they did not experience any stigmatization 
among the different contexts of cancer care and social 
surroundings. This group consists of four participants (ID 
nos. 36, 48, 63 and 87), who have in common that they 
have breast cancer for the first time (no relapse) and have 
minimal therapy—surgery and, in some cases, hormone 
therapy. Another characteristic of this first group is their 
higher average age (74 years) compared to the other two 
groups. Additionally, two of the men are still suffering 
from other types of cancer or have already experienced 
another cancer.
In contrast to that group, another group of MBCP 
experienced much more stigmatization during their pro-
cess of disease (“stigmatized”), as evidenced within the 
Dimensions of stigmatization and the Context of stigmati-
zation (Table 3), having more aspects or rather higher 
rates in some contexts (cancer care and social surround-
ings). To be part of this group, the participants need to 
have experiences in ⩾5 categories of stigmatization 
(counted crosses [x] in Dimensions of stigmatization and 
all values ⩾3 in Context of stigmatization). Within this 
group, there are seven participants (ID nos. 11, 16, 32, 52, 
67, 78, 82). All of them have received more types of ther-
apy than the “not stigmatized” group and two of them had 
a relapse (all relapse cases are within this group). The 
average age of those men is much lower than in Group 1 
(62 years).
The third group of MBCP represents those who expe-
rienced “average stigma levels,” as their level of stigma-
tization is located in the middle of the former two groups. 
It is the biggest group, consisting of all participants (N = 
16) who experienced more than “no stigmatization” and 
less than a lot (i.e., stigmatization in ⩾2/3 and <5 cate-
gories). They have an average age of 68 years, which is 
between the ages of groups 1 and 2. The stage of cancer 
varies among the members of this group, from a lower to 
a higher stage in regard to the therapy. All participants 
within this group have breast cancer for the first time.
Discussion
This study aimed to determine how MBCP feel about suf-
fering from a “woman’s disease.” To address this research 
question, it investigated (a) the surroundings in which the 
stigmatization is experienced; (b) the kind of stigmatiza-
tion experienced; (c) how, from the patients’ perspective 
the stigmatization can be reduced; and (d) if there is a 
typology of different stigma types in terms of the level of 
stigmatization.
The results reveal that MBCP feel stigmatized in dif-
ferent settings within the cancer care system as well as in 
social surroundings. The men mention more stigmatiza-
tion in the cancer care system and by female breast can-
cer patients within the care system than in their close 
social environment, based on the qualitative data. The 
quantitative data reveals a different picture, as most stig-
matization was significantly experienced within the 
working environment, followed by stigmatization in the 
cancer care system—within rehabilitation. The reasons 
Midding et al. 2203
for this difference may be an issue of measurement. In 
general, stigma rates in the quantitative analysis are low. 
In comparison to the other rates, those of exclusion 
within rehabilitation and working environment are 
higher. Nevertheless, they are not high absolutely. 
Another explanation for this difference in the qualitative 
and quantitative results may be that stigma was mea-
sured indirectly, by the feeling of exclusion. Maybe for 
MBCP, feeling excluded is not the same as feeling stig-
matized. For example, in the working environment the 
men might feel excluded because they are no longer par-
ticipating in the lived-in working environment after their 
cancer diagnosis, but this does not have to mean that they 
feel stigmatized by colleagues and superiors. Results of 
other studies support this interpretation of the results, as 
they indicate that there is low stigmatization in the work 
context (Ernst, Mehnert, Taubenheim, et al., 2017; Fife 
& Wright, 2000).
Transferring the aspect of feeling excluded to the other 
high rate of stigma (i.e., rehabilitation), it can mean that 
MBCP are feeling excluded from the group of female 
breast cancer patients because they are not part of this 
group. In the absence of a specialized rehabilitation cen-
ter for MBCP, they are going to the same institutions as 
women do and mostly constitute a minority among the 
female breast cancer patients. MBCP reported that often 
they are not allowed to visit the same programs as female 
breast cancer patients. For many MBCP it is the first time 
they are in such close contact with female breast cancer 
patients within rehabilitation programs. All these aspects 
mentioned may lead to the feeling of being excluded as a 
man in a rehabilitation surrounding that is dominated by 
women and designed for female breast cancer patients.
In the context of the private social surroundings, it was 
observed that MBCP experience significantly most stigma 
or exclusion within the work-related context. A reason this 
feeling is much higher than in other social surroundings, 
such as family or friends, may be connected to the role 
within the working environment. When getting ill, the role 
expectation as a working person can no longer be fulfilled, 
which may lead to stigmatization. At the same time, this 
role loss can be seen as a social effect of stigmatization, as 
Link and Phelan (2001) state within their theory of label-
ing approach. Stigmatization in the work-related context 
is not only the case for breast cancer but an issue of cancer 
in general (Ernst, Mehnert, Taubenheim, et al., 2017). A 
man might assume that he cannot continue to fulfill his 
role of feeding his family, which can lead to self-stigmati-
zation. The working environment is not very intimately 
connected to the person, unlike friends or the family. 
Within those closer social environments, there is often 
more understanding toward the individual’s needs and 
worries and the efficiency aspect does not have the same 
priority as within the working context.
Referring to the different dimensions of stigmatiza-
tion, it was identified that the category Experiences of 
stigmatization was most prevalent among the patients. It 
includes aspects demonstrating the unique position of the 
men regarding gender aspects. Many men feel they are in 
an exclusive position (Being the only rooster in the yard), 
which can be regarded as a positive kind of stigmatization 
because the men experienced more attention from the 
providers than other (female) patients did. Men are also 
experiencing Sexual stigmatization, as breast cancer is 
known as a typical women’s disease among the providers 
and the other patients. As a result, providers act according 
to these role expectations and regard MBCP as women 
initially. There is confusion about the role expected of a 
breast cancer patient if the disease is not automatically 
connected with femaleness anymore. This confusion is 
intensified by the fact presented within the category 
Ignorance that breast cancer in men is mostly unknown.
In relation to the Bodily dimension, the visible aspects 
of the disease, such as the scar on the breast or the loss of 
hair, were perceived differently in men. Pituskin et al. 
(2007) report similar results, stating that men differ in per-
ceived stigmatization because of the scar. The loss of hair 
has not been mentioned in any studies on MBC so far, 
maybe because hair loss is seen as a typical problem for 
female (breast) cancer patients. Trusson and Pilnic (2017) 
note that hair loss can be very traumatic for female breast 
cancer patients, but physicians often underrate it. As some 
men within this study demonstrate, losing hair can also be 
a problem for MBCP especially losing the beard, as it is a 
typical element of masculinity. As a disease becomes out-
wardly visible (e.g., formation of the scar on the breast or 
the loss of hair after cancer therapy), it often interferes 
with the social interactions because from this point on, 
one is identified as being sick and cannot fulfill one’s role 
expectations in society as a functioning member of society 
(Parsons & Turner, 2005; Reuter, 2015). Cancer patients 
are seen as goners, who came back to life (Holmberg, 
2005; Reuter, 2015). Physicality is gaining in importance 
in performance-oriented societies, not least because of the 
boom in health and fitness with its corresponding ideal of 
beauty (Reuter, 2015), and does not stop when it comes to 
fulfilling the roles of gender seen as typically female or 
male. Breast cancer can produce changes in body image, 
as some men feel emaciated due to the loss of physical 
strength (maleness) by cancer therapy.
In terms of indirect stigmatization, MBCP mentioned 
receiving questioning glances from other female patients 
and feeling observed within this women-dominated area 
of breast cancer care. This feeling may arise because 
breast cancer is connected with femaleness in society and 
being a man in this breast cancer care surrounding does 
not correspond to the social norms. As Hohmeier (1975) 
describes, stigmatization takes place to protect the social 
2204 American Journal of Men’s Health 12(6)
norm as well as the own identity—within this context—
of female breast cancer patients.
Therefore, MBCP feel self-stigmatization, sensing 
they are intruding into a women’s area, and women or 
female breast cancer patients want to protect their iden-
tity as breast cancer patients and hence consider MBCP 
as intruders.
Some MBCP sensed they were receiving different 
treatment than female breast cancer patients. Prior stud-
ies arrived at similar outcomes, as MBCP felt ignored by 
physicians (Pituskin et al., 2007) or experienced isola-
tion in treatment because they had to use separate 
entrances and waiting rooms in some clinics (Donovan 
& Flynn, 2007).
To reduce stigmatization in the future, the participants 
wish for awareness and equality of cancer care, so that 
breast cancer is not seen as an only woman’s disease any-
more. In concurrence with the literature, increased aware-
ness is needed to make the disease more public in general 
and in the cancer care system, as ignorance of MBC is a 
major issue within those areas (Iredale et al., 2006; 
Pituskin et al., 2007; White et al., 2011).
For equality in breast cancer care, the results revealed 
that the needs of MBCP should be considered in cancer 
care, in the form of gender-neutral documents and infor-
mation materials. Similarly, other studies advocate the 
creation of breast cancer information material (France 
et al., 2000; Pituskin et al., 2007) or separate sections 
(Williams et al., 2003) within the information specifically 
for men.
The three stigma groups identified in the research 
help to explain stigmatization of MBCP as they reveal 
the effect of age and extent of cancer treatment: With 
increasing age, the experienced stigmatization seems to 
decrease, as demonstrated by the contrary groups, the 
“not stigmatized” and the “stigmatized.” Within the “not 
stigmatized” cohort, the comparatively older age of the 
participants seems to protect from stigmatization because 
of some aspects that are connected with older age. First, 
all of the men are retired, so they are not in the work 
context anymore and hence do not experience exclusion. 
Second, at a relatively older age one may have more 
experiences with cancer, as people in the social sur-
roundings may have cancer and so it may seem more 
normal. Additionally, two of the men experienced cancer 
themselves, so they may have become hardened by that 
experience. A third explanation may be the perception of 
masculinity changes with age. Therefore, the men within 
this group might not have experienced any sexual stig-
matization. Maybe the gender factor is not that important 
anymore for them compared to men of a younger age. 
Also, one of the men within this group is already suffer-
ing from another disease, which is dominating his life, so 
he did not attach too much importance to breast cancer. 
In contrast, the men within the “stigmatized” cohort have 
the youngest age on average and some of them are still 
working, so they also have a higher potential to feel 
excluded compared to the “not stigmatized” participants, 
who are retired.
Concerning the effect of extent of cancer treatment, 
the participants within the group of the “not stigma-
tized” had not had a long period of treatment and conse-
quently had few points of contact (Bloom, Stewart, 
Chang, & Banks, 2004) with the cancer care system. In 
addition, none of them experienced chemotherapy or 
adjuvant radiation, so they did not lose any hair, and as 
such, the disease is not visible for others at first sight. It 
is only when the shirt is removed that the scar is visible. 
Among the three groups, the “stigmatized” members 
experienced more cancer treatment, so they have more 
potential to be stigmatized: first, within the different 
steps of cancer care and second, from the effects the 
treatment has on the body like losing hair because of 
chemotherapy. Therefore, the disease becomes visible 
for everyone in society and increases the potential for 
stigma attacks, as already discussed within the category 
Bodily dimension.
The literature recognizes that sociodemographic 
aspects like age can play an important role when it comes 
to stigmatization (Bloom et al., 2004; Moyer & Salovey, 
1996). In some studies, associations with educational 
level and stigmatization were reported (Holman, 2015; 
Tripathi et al., 2017), but this effect cannot be observed in 
the current investigation.
Interestingly, some men reported in the interviews 
that they have not experienced any stigmatization over 
the course of their breast cancer journey, as Table 3 
reveals (category: No subjective stigma). However, 
aspects of stigmatization could be identified within the 
interviews. Maybe this difference in subjective percep-
tion and narration is because those participants have not 
purposely acknowledged their experiences or feelings 
of stigmatization, and hence, these only appear within 
narrations. Besides, it can be regarded as a kind of pro-
tective mechanism to consider oneself as not 
stigmatized.
It can be recognized that other cancer patients are 
also stigmatized—not only MBCP—and there might 
exist worse stigmatizations than the men within this 
study experienced. As already stated, stigmatization is 
very individual and subjective. If someone conceives 
something as stigmatizing, it can sometimes also be 
connected with the individual’s perception. However, 
this study did not set out to compare the level of stigma-
tization of several groups. Instead, it aims to call atten-
tion to the problem of stigmatization of MBCP to raise 
the awareness of this issue among society and caretak-
ers. The study also wanted to point out, from a patients’ 
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perspective, how their experienced stigmatization can 
be reduced. It can be appreciated that stigmatization of 
MBCP often happens by mistake and in good faith, 
which highlights the importance of raising public 
awareness of the disease.
Strengths and Limitations
The strengths of this study are the diverse sample (due to 
the purposeful sampling), the high response rate of the 
MBCP, and the mixed methods design. Accordingly, the 
results could be described from a broad perspective and 
for a large sample of MBCP in Germany.
As limitations, it can be stated that this study is 
restricted to the German cancer care system because the 
health-care systems vary dramatically; therefore, the 
results cannot be transferred unrestrictedly to other 
countries with different cancer care systems. Furthermore, 
the data of disease-related characteristics and breast can-
cer treatment were gathered by the participants, intro-
ducing the possibility of mistakes if the participant’s 
knowledge was not accurate.
(Practical) Implications
As MBCP experience most stigmatization in the cancer 
care system, there is a need to devise strategies to manage 
this, including a need for creating awareness and provid-
ing equality of cancer care so that breast cancer is not 
seen only as a woman’s disease anymore. As MBCP 
within this study stated, specific needs of MBCP should 
be considered in cancer care.
Overall, there is a need for publicity and increased 
attention about MBCP to prevent stigmatization. As men-
tioned by (Ernst, Mehnert, Taubenheim, et al., 2017), 
cancer-specific approaches must be taken against stigma-
tization to avoid psychological and psychosocial prob-
lems, because every group of cancer patients has different 
needs (Ernst, Mehnert, Dietz, Hornemann, & Esser, 2017). 
For MBCP, one idea is to place a blue stripe on the pink-
colored breast cancer ribbon as a symbol for MBC. 
Moreover, the restricted connection of breast cancer with 
femaleness must be dismissed, which demands a gender-
neutral affiliation of breast cancer—in society as well as 
in breast cancer care.
Body image problems of MBCP like the scar on the 
breast or the loss of hair should also be taken more 
seriously by the health-care professionals, as these 
can be traumatic for all cancer patients. For instance, 
periwigs for male patients should be offered by physi-
cians. Implications for further research are the multi-
variate testing of the stated hypotheses, notably, the 
correlation of stigmatization, age, and intensity of 
cancer care.
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Notes
1. Within this standardized questionnaire, the men were 
asked for their willingness to conduct an interview. If they 
agreed, the men were called, during which their desire 
was confirmed and an appointment made for a personal 
interview.
2. The interview guideline included questions about how 
the participants experienced the cancer care during their 
course of disease, which persons were involved in what 
way, how the participants experienced their disease, and 
how they dealt with their breast cancer disease. The nar-
rative-generating introducing question was “If you think 
back to the time before you were diagnosed with breast 
cancer. What was it like when you noticed signs of physi-
cal change/possible illness in your body for the first time?”
3. Because we did not know if the participants would meet 
the exclusion criteria before having contacted them per-
sonally, we sent the questionnaire to all interested MBCP 
we had established contact with. Also, the declaration of 
consent was sent with the questionnaire.
The questionnaire was sent before the interviews were 
conducted to facilitate a purposeful selection of partici-
pants for the qualitative interviews as described earlier.
4. Coding was inductive from the data and deductive based 
on the literature, especially from Link and Phelan (2001) 
and Reuter (2015).
5. For coding of stigmatization within the interview mate-
rial, a systematic coding system was developed. Every 
aspect within the transcripts that described stigmatization, 
according to the definition stated within this article, was 
coded as stigmatization (among the related subcategories). 
Further information about the coding process is available 
from the authors.
6. For interpreting Table 3: The qualitative and quantitative 
results of stigmatization and as well demographic aspects 
of participants are merged within this table per participant. 
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The heading Context of stigmatization comprises the 
results of the quantitative analysis of experiences of stig-
matization during the course of cancer treatment and in 
private surroundings described in Table 2. The values 1–5 
demonstrate the intensity of stigmatization (1) never, (2) 
rarely, (3) sometimes, (4) often, and (5) always. The aspect 
Dimensions of stigmatization shows the results of the qual-
itative analysis from the interview per participant, which 
are the five main categories of stigmatization that could be 
found within the interviews. The category No subjective 
stigma means that the participant stated within the inter-
view that he experienced no stigmatization concerning his 
breast cancer disease.
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